Pharmacological aspects of successful long-term analgesia

Clinical Rheumatology

Volumn 25, Issue SUPPL. 7, 2006, Pages

  Raffa, Robert ^a  

^a TEMPLE UNIVERSITY SCHOOL OF PHARMACY   (United States)

Author keywords

COX 2 inhibitor; Long term analgesia; Multi modal analgesia; NSAID; Paracetamol plus tramadol; Synergistic analgesia

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; ARACHIDONIC ACID; BUPRENORPHINE; COCODAMOL; CODEINE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DEXTROPROPOXYPHENE; DEXTROPROPOXYPHENE PLUS PARACETAMOL; ENDORPHIN DERIVATIVE; ENKEPHALIN DERIVATIVE; HYDROCODONE; IMIPRAMINE; MORPHINE; MU OPIATE RECEPTOR; NALOXONE; NEUROTRANSMITTER RECEPTOR; OPIATE ANTAGONIST; OPIATE DERIVATIVE; OXYCODONE; PARACETAMOL; PROSTACYCLIN; PROSTAGLANDIN; ROFECOXIB; SEROTONIN RECEPTOR; TRAMADOL; UNINDEXED DRUG;

ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC PAIN; CLINICAL DECISION MAKING; CLINICAL TRIAL; CONSTIPATION; DIGESTIVE SYSTEM ULCER; DRUG BINDING SITE; DRUG DEPENDENCE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; KIDNEY DISEASE; LABORATORY TEST; LIVER FAILURE; LIVER INJURY; LONG TERM CARE; NAUSEA; NEPHROTOXICITY; NONHUMAN; PATIENT CARE; PRESCRIPTION; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; REVIEW; SKIN DISEASE; SOMNOLENCE; STRUCTURE ANALYSIS; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; TREATMENT OUTCOME;

ACETAMINOPHEN; ANALGESICS, NON-NARCOTIC; ANALGESICS, OPIOID; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; PAIN; QUALITY OF LIFE; TRAMADOL;

EID: 33745324079     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-006-0201-x     Document Type: Review

References (52)

1. Smith BH, Elliott AM, Chambers WA, Smith WC, Hannaford PC, Penny K (2001) The impact of chronic pain in the community. Fam Pract 18:292-299
2. Hawkey CJ (1999) COX-2 inhibitors. Lancet 353:307-314
3. Simmons DL, Botting RM, Hla T (2004) Cyclooxygenase isozymes: The biology of prostaglandin synthesis and inhibition. Pharmacol Rev 56:387-437
4. Komhoff M, Grone HJ, Klein T, Seyberth HW, Nusing RM (1997) Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: Implication for renal function. Am J Physiol 272:F460-F468
5. Lanas A, Perez-Asia MA, Feu F et al (2005) on behalf of the Investigators of the Asociación Española de Gastroenterología. A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory use. Am J Gastroenterol 100:1685-1693
6. Smalley WE, Ray WA, Daugherty JR et al (1995) Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons. Am J Epidemiol 141:539-545
7. Cronstein B (2002) Cyclooxygenase-2-selective inhibitors: Translating pharmacology into clinical utility. Cleve Clin J Med 69(Suppl 1):S1-S19
8. Mukherjee D, Nissen SE, Topol EJ (2001) Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286:954-959
9. Solomon DH, Schneeweiss S, Levin R, Avorn J (2004) Relationship between COX-2 specific inhibitors and hypertension. Hypertension 44:140-145
10. US FDA memorandum (NDA 21-042, S-007). Cardiovascular safety review, February 1, 2001 http://www.fda.gov/ohrms/dockets/ac/01/briefing/ 3677b2_06_cardio.pdf. Accessed November 2005
11. US FDA Press release, 30 September 2004. FDA issues public health advisory on Vioxx as its manufacturer voluntarily withdraws the product. http://www.fda.gov/bbs/topics/news/2004/NEW01122.html. Accessed November 2005
12. US FDA memorandum, April 6, 2005. http://www.fda.gov/cder/drug/infopage/ COX2/NSAIDdecisionMemo.pdf. Accessed November 2005
13. EMEA Press release, 17 October 2005. European Medicines Agency update on non-selective NSAIDs. http://www.emea.eu.int/htms/hotpress/ h29896405.htm. Accessed November 2005
14. US FDA alert, 04/07/05. Valdecoxib (marketed as Bextra). http://www.fda.gov/cder/drug/InfoSheets/HCP/valdecoxibHCP.pdf. Accessed November 2005
15. EMEA statement, 7 April 2005. European Medicines Agency statement on the suspension of use of Bextra. http://www.emea.eu.int/htms/hotpress/ h12163705.htm. Accessed November 2005
16. EMEA Press release, 27 June 2005. European Medicines Agency concludes action on COX-2 inhibitors. http://www.emea.eu.int/pdfs/human/press/pr/ 20776605en.pdf. Accessed November 2005
17. EMEA Press release, 2 August 2005. http://www.emea.eu.int/pdfs/human/ press/pr/24732305en.pdf. Accessed November 2005
18. Prior MJ, Cooper KM, May LG, Bowen DL (2002) Efficacy and safety of acetaminophen and naproxen in the treatment of tension-type headache. A randomized, double-blind, placebo-controlled trial. Cephalalgia 22:740-748
19. Lipton RB, Baggish JS, Stewart WF, Codispoti JR, Fu M (2000) Efficacy and safety of acetaminophen in the treatment of migraine: Results of a randomized, double-blind, placebo-controlled, population-based study. Arch Intern Med 160:3486-3492
20. Stannard C, Booth S (2004) Pain. Elsevier-Churchill Livingstone, London
21. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines (2000). Recommendations for the medical management of osteoarthritis of the hip and knee. Arthritis Rheum 43:1905-1915
22. Von Mering J (1893) Beiträge zur Kenntniss der Antipyretica. Therap Monatshefte 7:577-578
23. Raffa RB, Stone DJ Jr, Tallarida RJ (2000). Discovery of "self-synergistic" spinal/supraspinal antinociception produced by acetaminophen (paracetamol). J Pharmacol Exp Ther 295:291-294
24. Raffa RB, Codd EE (1996) Lack of binding of acetaminophen to 5-HT receptor or uptake sites (or eleven other binding/uptake assays). Life Sci 59:PL37-PL40
25. Raffa RB et al (2005) Netter's illustrated pharmacology. Icon Learning Systems, Teterboro, NJ
26. VA/DoD clinical practice guideline for the management of opioid therapy for chronic pain. Downloaded from: http://www.oqp.med.va.gov/cpg/cot/ ot_base.htm; summary at: http://www.oqp.med.va.gov/cpg/cot/G/ OT_Sum.pdf. September 2003. Accessed November 2005
27. Auret K, Schug SA (2005) Underutilisation of opioids in elderly patients with chronic pain. Drugs Aging 22:641-654
28. Raffa RB, Friderichs E, Reimann W, Shank RP, Codd EE, Vaught JL (1992) Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic. J Pharmacol Exp Ther 260:275-285
29. Bamigbade TA, Davidson C, Langford RM, Stamford JA (1997) Actions of tramadol, its enantiomers and principal metabolite, O-desmethyltramadol, on serotonin (5-HT) efflux and uptake in the rat dorsal raphe nucleus. Br J Anaesth 79:352-356
30. Grond S, Sablotzki A (2004) Clinical pharmacology of tramadol. Clin Pharmacokinet 43:879-923
31. FDA Public Health Advisory, 7 April 2005. FDA announces important changes and additional warnings for COX-2 selective and non-selective non-steroidal anti-inflammatory drugs (NSAIDs) http://www.fda.gov/cder/ drug/advisory/COX2.htm. Accessed November 2005
32. Committee on Safety of Medicines 2005. Current Problems in Pharmacovigilance. Volume 30, October 2004. Downloaded from: http://www.mca.gov.uk/aboutagency/regframework/csm/csmhome.htm/ http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/ currentproblems/currentproblems.htm
33. Schou J, Angelo H, Dam W, Jensen K, Christensen JM (1978) Pharmacokinetics of dextropropoxyphene in acute poisoning. Arch Toxicol Suppl 1:343-346
34. Gibson TP, Giacomini KM, Briggs WA, Whitman W, Levy G (1980) Propoxyphene and norpropoxyphene plasma concentrations in the anephric patient. Clin Pharmacol Ther 27:665-670
35. Sloth Madsen P, Strom J, Reiz S, Bredgaard Sorensen M (1984) Acute propoxyphene self-poisoning in 222 consecutive patients. Acta Anaesthesiol Scand 28:661-665
36. Crome P, Gain R, Ghurye R, Flanagan RJ (1984) Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in elderly hospital patients after single and multiple doses of distalgesic. Preliminary analysis of results. Hum Toxicol 3:41S-48S (Suppl)
37. Flanagan RJ, Johnston A, White AS, Crome P (1989) Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage. Br J Clin Pharmacol 28:463-469
38. Pearson RM (1984) Pharmacokinetics of propoxyphene. Hum Toxicol 3:37S-40S (Suppl)
39. Cascorbi I (2003) Pharmacogenetics of cytochrome P4502D6: Genetic background and clinical implication. Eur J Clin Invest 33(Suppl 2):17-22
40. Schnitzer T (2003) The new analgesic combination tramadol/acetaminophen. Eur J Anaesthesiol 28:13-17 (Suppl)
41. Tallarida RJ, Raffa RB (1996) Testing for synergism over a range of fixed ratio drug combinations: Replacing the isobologram. Life Sci 58:PL23-PL28
42. Emkey R, Rosenthal N, Wu SC, Jordan D, Kamin M, CAPSS-114 Study Group (2004) Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add-on therapy for osteoarthritis pain in subjects receiving a COX-2 nonsteroidal antiinflammatory drug: A multicenter, randomized, double-blind, placebo-controlled trial. J Rheumatol 31:150-156
43. Edwards JE, McQuay HJ, Moore RA (2002) Combination analgesic efficacy: Individual patient data meta-analysis of single dose oral tramadol plus acetaminophen in acute postoperative pain. J Pain Symptom Manage 23:121-130
44. Ruoff GE, Rosenthal N, Jordan D, Karim R, Kamin M; Protocol CAPSS-112 Study Group (2003) Tramadol/acetaminophen combination tablets for the treatment of chronic lower back pain: A multicenter, randomized, double-blind, placebo-controlled outpatient study. Clin Ther 25:1123-1141
45. Mullican WS, Lacy JR, TRAMAP-ANAG-006 Study Group (2001) Tramadol/ acetaminophen combination tablets and codeine/acetaminophen combination capsules for the management of chronic pain: A comparative trial. Clin Ther 23:1429-1445
46. Bennett RM, Kamin M, Karim R, Rosenthal N (2003) Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. Am J Med 114:537-545
47. Smith AB, Ravikumar TS, Kamin M, Jordan D, Xiang J, Rosenthal N, CAPSS-115 Study Group (2004) Combination tramadol plus acetaminophen for postsurgical pain. Am J Surg 187:521-527
48. Fricke JR, Karim R, Jordan D, Rosenthal N (2002) A double-blind, single-dose comparison of the analgesic efficacy of tramadol/ acetominophen combination tablets, and placebo, after surgery. Clin Ther 24:953-968
49. Silverfield JC, Kamin M, Wu SC, Rosenthal N, CAPSS-105 Study Group (2002) Tramadol/acetaminophen combination tablets for the treatment of osteoarthritis flare pain: A multicenter, outpatient, randomized, double-blind, placebo-controlled, parallel-group, add-on study. Clin Ther 24:282-297
50. Peloso PM, Fortin L, Beaulieu A, Kamin M, Rosenthal N, Protocol TRP-CAN-1 Study Group (2004) Analgesic efficacy and safety of tramadol/ aceta0minophen combination tablets (Ultracet) in treatment of chronic low back pain: A multicenter, outpatient, randomized, double blind, placebo-controlled trial. J Rheumatol 31:2454-2463
51. Hippisley-Cox J, Coupland C (2005) Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: Population based nested case-control analysis. BMJ 330:1366
52. US FDA information page, April 7, 2005. COX-2 selective (includes Bextra, Celebrex, and Vioxx) and non-selective non-steroidal anti-inflammatory drugs (NSAIDs). http://www.fda.gov/cder/drug/infopage/ COX2/default.htm. Accessed November 2005